|
Thursday 14th September 2023 |
Text too small? |
Cannasouth Limited (NZX: CBD ) has exported to Australia its first commercial shipment of its high-purity cannabidiol (CBD) isolate, a cannabis-based, active pharmaceutical ingredient (API). This is a first for Aotearoa New Zealand’s medicinal cannabis industry.
This CBD isolate was manufactured in New Zealand to PIC/s Good Manufacturing Practice (GMP) standards and verified by the Medicinal Cannabis Agency. This first shipment is the forerunner of greater volumes of API exports for the local industry, signalling the demand for high-quality, GMP certified cannabis-based APIs on the international stage.
This signals the next growth phase for Cannasouth and the medicinal cannabis industry.
-ENDS-
No comments yet
KMD strengthens balance sheet with debt refinance
GXH - Green Cross Health Limited - Annual Shareholders' Meeting
VGL - Cineplexx Europe signs to Operational Excellence
STU - Steel & Tube - Director Resignation - Steve Reindler
Ryman Healthcare Limited Notice of Meeting 2026
Spark New Zealand FY26 Results Announcement Date
OCA - Oceania bond offer - interest rate set
VNT - Appointment of Managing Director and Group CEO of Ventia
ATM - a2MC declares $300 million special dividend
June 25th Morning Report